Sun Pharmaceutical Industries Limited (SUNPHARMA) announced the establishment of the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai, marking a significant commitment to advancing dermatologic care. The endowed professorship, supported by a $2.5 million endowment from Sun Pharma, will fund academic leadership in dermatology in perpetuity, beginning with Dr. Mark G. Lebwohl as its inaugural incumbent.

Academic Leadership in Dermatology

Dr. Lebwohl, internationally recognized for his contributions to psoriasis research and treatment, will serve as the inaugural professor in this new role. His work has significantly influenced the understanding of inflammatory skin diseases and shaped standards of care that have improved patient outcomes worldwide. The professorship aims to advance research and training, translating emerging knowledge into better care and preparing future leaders in dermatology.

Commitment to Dermatology Care

Ahmad Naim, M.D., Senior Vice President and Chief Medical Officer, North America, emphasized Sun Pharma’s long-term commitment to fostering academic leadership needed to pursue new ideas and strengthen care for generations to come. ‘At Sun Pharma, we believe meaningful progress in dermatology care requires supporting the people and institutions advancing the field today and in the future,’ he stated.

Future of Dermatology

The establishment of this professorship reflects a shared belief that investing in scientific excellence and academic leadership ultimately leads to better outcomes for patients around the world. As the second-largest pharmaceutical dermatology company in the U.S. by prescription volume, Sun Pharma is dedicated to advancing patient care through scientific innovation, education, and partnerships.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Sun moves sideways over three months, with neither buyers nor sellers taking control. The PEG reaches 3.38. The stock trades on brand and index weight, not on growth. Premium net margins of 20.2% demonstrate strong cost discipline and a wide competitive moat. The stock holds at 48% of its 52-week range with RSI at 40. In other words, neither side has a clear edge right now. Revenue grows at 10.4% and profits at 10.6%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Sun Pharmaceutical Industries Limited.

Indegene Limited (INDGN) held its most influential Digital Summit 2026, signaling its growing influence in AI and enterprise transformation. The summit, held at the National Constitution Center in Philadelphia, attracted 120+ senior pharma leaders, with 50% decision makers and 70% Directors+. The event featured 4 keynotes, 8 panels, and presentations from industry leaders in commercial, medical, digital, data, and technology sectors.

Establishing Leadership in AI-Native Pharma Enablement

Indegene’s AI and platform capabilities emerged as one of the strongest themes of the summit. With 8 sessions exploring AI’s impact and performance from industry, leader, and capability perspectives, the summit offered a direct view into Indegene’s capabilities. The event reinforced the shift from AI experimentation to enterprise transformation.

A Venue Symbolizing Leadership and Enduring Ideas

The National Constitution Center, Philadelphia, symbolized leadership, transformation, and the future of life sciences. The ‘Freedom Rising Show’ and other experience zones delivered a premium executive experience, enabling deeper engagement with existing and prospective clients. The venue strengthened executive engagement across the U.S. life sciences ecosystem.

Future-Ready Healthcare and Strategic Positioning

IDS 2026 signaled a shift towards future-ready healthcare, with Indegene emerging as a strategic partner, AI innovator, and industry convenor. The event highlighted the importance of reimagined operating models, AI-mediated discovery, and agile organizations combining human expertise, AI intelligence, and continuous learning.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Indegene Limited

Indegene Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.

Indegene gains 21.7% over three months and trades near its 52-week highs. The PEG of 2.46 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Buyers show up with 1.7x the volume of sellers. Moreover, they dominated on 15 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 21.7% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.

Zydus Lifesciences Limited (ZYDUSLIFE) announced today a significant milestone in its U.S. operations by launching the first generic version of Adempas® (riociguat) in partnership with MSN Laboratories Private Limited (MSN). This launch marks the first-to-market availability of riociguat tablets in the U.S., offering a lower-cost alternative to patients suffering from pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

First-to-Market Launch

The riociguat tablets, available in five strengths (0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg), are now approved by the United States Food and Drug Administration (USFDA) as a generic equivalent of Adempas® tablets. This development is a testament to the strength of Zydus’ complex-generics pipeline and its ability to execute day-one launches in specialty categories.

Impact on Patients

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, emphasized the importance of this launch, stating, ‘Being first to market with generic riociguat is a milestone for our U.S. business and for patients with pulmonary hypertension.’ Riociguat is a soluble guanylate cyclase (sGC) stimulator that helps improve exercise capacity and functional class for patients with PAH and CTEPH, conditions that are rare, progressive, and life-threatening. This launch ensures that more patients can access this critical therapy at a reduced cost.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Zydus Lifesciences Limited

Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.69 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock gains 1.7% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.